Importantly, genetic and pharmacological destruction of GSK3B-mediated T334 phosphorylation leads to HR repair deficiency and makes cancer cells susceptible to synthetic lethality of PARPi therapy independent of BRCA1 status. This evidence concerns the gene BRCA1 and cancer.